Cytomegalovirus (CMV) Treatment Market – By Drug Type (Valganciclovir, Ganciclovir, Cidofovir, Foscarnet), Application, Route of Administration, Distribution Channel - Global Forecast, 2024 – 2032

Cytomegalovirus Treatment Market Size

Cytomegalovirus Treatment Market size was valued at USD 474.6 million in 2023 and is anticipated to register a CAGR of 6.6% between 2024 and 2032. This growth is propelled by increasing awareness and prevalence of CMV infection, as well as the development of new and effective treatments. For instance, according to the National Library of Medicine report of August 2023, CMV infects approximately 60% to 70% of adults in developed countries and nearly 100% in developing economies, driving demand for CMV treatment.
 

Cytomegalovirus (CMV) treatment involves the use of antiviral drugs to manage CMV infections. CMV is a common virus known to cause serious complications, particularly in individuals with weakened immune systems such as those with HIV/AIDS, organ transplant recipients, and newborns. The primary goals of treatment are to alleviate symptoms, halt disease progression, and improve patient outcomes.
 

Cytomegalovirus Treatment Market Trends

• The rising prevalence of viral infections among AIDS patients, stemming from their compromised immune systems, is expected to drive the demand for cytomegalovirus drugs. Due to diminished immune function, individuals with HIV/AIDS are more susceptible to opportunistic infections, including cytomegalovirus (CMV). CMV infections can result in severe complications, especially in immunocompromised individuals like AIDS patients. Consequently, there is an increasing demand for effective CMV treatment options to manage and alleviate the impact of these infections on patient health and outcomes.
   
• For instance, as per the World Health Organization (WHO) in November 2022, approximately 38.4 million individuals were living with HIV in 2021, comprising 36.7 million adults and 1.7 million children affected by the virus. Consequently, the high prevalence of infectious diseases among AIDS patient is expected to drive the market growth.
   

CMV Treatment Market Analysis

Based on the drug type, the global market is classified into valganciclovir, ganciclovir, cidofovir, foscarnet, and other drug types. The ganciclovir drug type dominated the market with revenue of USD 162.5 million in 2023.
 

• Ganciclovir is a first-line antiviral medication for the treatment of CMV infections. It inhibits viral replication by targeting the viral DNA polymerase enzyme, making it an essential component of CMV treatment regimens. Its proven efficacy in managing CMV infections contributes to its widespread use in clinical practice.
   
• Additionally, the increasing number of solid organ and hematopoietic stem cell transplants globally contributes to a surging incidence of CMV infections among transplant recipients, thereby bolstering segment expansion.

Based on application, the cytomegalovirus treatment market is classified into stem cell transplantation, organ transplantation, congenital CMV infection, and other applications. The stem cell transplantation segment held the highest business share of 38.3% in 2023.
 

• Stem cell transplantation stands to gain from the integration of new cell types, presenting significant opportunities for companies to fortify their market presence. Consequently, the number of companies venturing into cell therapy development has markedly increased in recent years.
   
• Moreover, rising government and private sector funding for stem cell therapy clinical trials, the implementation of effective stem cell therapy manufacturing guidelines, and the proven effectiveness of products are expected to be key growth drivers for the market segment.
   

Based on route of administration, the cytomegalovirus treatment market is classified into oral and intravenous. The intravenous segment is expected to hold the highest revenue throughout the forecast period.
 

• The IV route of administration is preferred in acute care settings such as hospitals and infusion centers, where patients with severe CMV infections, such as CMV retinitis or systemic CMV disease, require immediate and intensive treatment. Thus, demand for injectable in CMV treatment is anticipated to grow in forthcoming years.
   
• Additionally, with the increasing emphasis on outpatient care and the shift towards ambulatory infusion services, there is a growing demand for IV CMV treatment options that can be administered in outpatient settings. This trend is driven by factors such as patient convenience, cost-effectiveness, and the desire to minimize hospital admissions.
   

Based on distribution channel, the CMV treatment market is classified into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies dominated the market with revenue of USD 219.9 million in 2023.
 

• Hospital pharmacies serve as a vital healthcare facility where patients receive specialized care, particularly those undergoing organ transplantation or with weaker immune systems. Hospital pharmacists have a range of CMV medications and antiviral treatments, ensuring that patients receive early and effective care.
   
• Hospital pharmacists serve as a key hub for CMV therapy since they are also prepared to manage the difficulties of treating CMV infections in a variety of patient demographics. Effective communication and coordination are further facilitated in the management of CMV patients by the collaborative character of healthcare teams in hospitals.

In 2023, North America secured a substantial market share in the global cytomegalovirus treatment market and is expected to dominate throughout the forecast period.
 

• Factors such as the increasing consumer awareness, growing incidences of cytomegalovirus infections, and the presence of key market players are some of the prominent factors that will contribute significantly to the market's expansion.
   
• For instance, according to an article released by NINDS in July 2022, CMV infects around 50% to 80% of adults each year by the age of 40 and is one of the most common congenital diseases in the U.S.
   

CMV Treatment Market Share

The competitive landscape of the cytomegalovirus treatment industry is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective cytomegalovirus (CMV) treatment.
 

CMV Treatment Market Companies

Prominent players operating in the CMV treatment industry are as mentioned below:

• Chimerix
• Clinigen Group PLC
• F. Hoffmann-La Roche Ltd
• Fresenius Kabi
• Genentech Inc.
• Gilead Sciences, Inc.
• Merck & Co. Inc
• Mylan N.V
• Pfizer, Inc.
• Takeda Pharmaceuticals
• Teva Pharmaceuticals Inc
• Thermo Fisher Scientific Inc.
   

Cytomegalovirus Treatment Industry News

• In September 2022, ProBioGen and the City of Hope entered in a commercial license agreement to use the AGE1.CR.pIX vaccine manufacturing platform for the Cytomegalovirus (CMV) vaccine. The commercial license agreement between ProBioGen and the City of Hope allowed the City of Hope to use the AGE1.CR.pIX platform to manufacture the CMV vaccine for clinical trials and commercial distribution. This partnership has helped company to accelerate the development and production of the CMV vaccine, which could potentially save many lives.
   
• In November 2021, Takeda Pharmaceutical received FDA approval for the product Maribavir which is used for the treatment of adults and pediatric patients aged 12 years or older with post-transplant cytomegalovirus infection/disease that is refractory to treatment. This product approval strengthens company’s overall market position.
   

The cytomegalovirus treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Valganciclovir
• Ganciclovir
• Cidofovir
• Foscarnet
• Other drug types

Market, By Applications

• Stem cell transplantation
• Organ transplantation
• Congenital CMV infection
• Other applications

Market, By Route of Administration

• Oral
• Intravenous

Market, By Distribution Channel

• Hospital pharmacies
• Retail Pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa